Company intelligence / Profile preview

Woebot Health

San Francisco, California, United Stateswoebothealth.com ↗

Ownership: Private
Employees: ~75
Development stage: Phase 2

Overview

Woebot Health has conducted 14 randomized controlled trials demonstrating that its AI-powered chatbot can form a therapeutic bond comparable to human therapists. The platform delivers evidence-based interventions for anxiety and depression with validated outcomes published in peer-reviewed literature[1].

Therapeutic areas: Psychiatry
Modalities: Non-pharmacological therapyDevice (AI-powered digital therapeutic/chatbot)
Industry: Digital Health Medical Devices

Drug pipeline

1 asset

WB001

Phase 2

Indications: Postpartum depression

Partnerships

Partners with payers (insurance), health systems/hospitals, virtual primary care companies to deliver scalable digital therapeutics

Beyond the preview

Go deeper on Woebot Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Woebot Health.

Explore the full profile